TW201632559A - 結合ｃｄ１３７之抗體治療劑 - Google Patents

結合ｃｄ１３７之抗體治療劑 Download PDF

Info

Publication number
TW201632559A
TW201632559A TW105105159A TW105105159A TW201632559A TW 201632559 A TW201632559 A TW 201632559A TW 105105159 A TW105105159 A TW 105105159A TW 105105159 A TW105105159 A TW 105105159A TW 201632559 A TW201632559 A TW 201632559A
Authority
TW
Taiwan
Prior art keywords
seq
referred
antibody
chain variable
variable domain
Prior art date
Application number
TW105105159A
Other languages
English (en)
Chinese (zh)
Inventor
約翰 迪森 葛瑞
周賀鉞
Original Assignee
索倫多醫療公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 索倫多醫療公司 filed Critical 索倫多醫療公司
Publication of TW201632559A publication Critical patent/TW201632559A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW105105159A 2015-02-22 2016-02-22 結合ｃｄ１３７之抗體治療劑 TW201632559A (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562119211P 2015-02-22 2015-02-22

Publications (1)

Publication Number Publication Date
TW201632559A true TW201632559A (zh) 2016-09-16

Family

ID=56690285

Family Applications (1)

Application Number Title Priority Date Filing Date
TW105105159A TW201632559A (zh) 2015-02-22 2016-02-22 結合ｃｄ１３７之抗體治療劑

Country Status (12)

Country Link
US (4) US10233251B2 (OSRAM)
EP (1) EP3258959A4 (OSRAM)
JP (1) JP2018508509A (OSRAM)
KR (1) KR20180016972A (OSRAM)
CN (1) CN107921104A (OSRAM)
AR (1) AR105313A1 (OSRAM)
AU (1) AU2016219772A1 (OSRAM)
CA (1) CA2977257A1 (OSRAM)
IL (1) IL254088A0 (OSRAM)
MX (1) MX2017010793A (OSRAM)
TW (1) TW201632559A (OSRAM)
WO (1) WO2016134358A1 (OSRAM)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018133139A1 (zh) 2017-01-21 2018-07-26 宁波知明生物科技有限公司 芍药苷-6'-o-苯磺酸酯在治疗干燥综合征的应用
US11459394B2 (en) 2017-02-24 2022-10-04 Macrogenics, Inc. Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereof
TWI842672B (zh) * 2017-04-13 2024-05-21 美商艾吉納斯公司 抗ｃｄ１３７抗體及其使用方法

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201203051D0 (en) * 2012-02-22 2012-04-04 Ucb Pharma Sa Biological products
KR101503341B1 (ko) 2014-03-12 2015-03-18 국립암센터 자가암항원 특이적 cd8+ t 세포의 분리 및 증식방법
AU2016219772A1 (en) * 2015-02-22 2017-09-21 Sorrento Therapeutics, Inc. Antibody therapeutics that bind CD137
CN107709367A (zh) * 2015-05-21 2018-02-16 鳄鱼生物科学公司 新型多肽
SG11201811184UA (en) 2016-06-20 2019-01-30 F Star Beta Ltd Lag -3 binding members
JP7461741B2 (ja) 2016-06-20 2024-04-04 カイマブ・リミテッド 抗ｐｄ－ｌ１およびｉｌ－２サイトカイン
BR112019000512A2 (pt) 2016-07-14 2019-04-24 Genmab A/S anticorpo, ácido nucleico, vetor de expressão, célula hospedeira, composição, métodos de tratamento de uma doença, para produzir um anticorpo biespecífico e para detectar se a reticulação entre as células que expressam cd40 e cd137 ocorre em uma amostra, uso de um anticorpo multiespecífico, e, kit
GB201612520D0 (en) 2016-07-19 2016-08-31 F-Star Beta Ltd Binding molecules
GB201619648D0 (en) * 2016-11-21 2017-01-04 Alligator Bioscience Ab Novel antibodies and uses thereof
EP3544628A4 (en) 2016-11-23 2020-11-18 Immunoah Therapeutics, Inc. 4-1BB BINDING PROTEINS AND THEIR USES
US10174122B2 (en) * 2017-01-06 2019-01-08 Eutilex Co., Ltd. Anti-human 4-1BB antibodies and uses thereof
IL322943A (en) 2017-07-11 2025-10-01 Compass Therapeutics Llc Agonist antibodies that bind human CD137 and their use
JOP20200016B1 (ar) * 2017-08-01 2022-10-30 Lilly Co Eli أجسام مضادة لـ cd137
US11512134B2 (en) 2017-08-01 2022-11-29 Eli Lilly And Company Anti-CD137 antibodies
KR102758346B1 (ko) * 2017-08-04 2025-01-24 젠맵 에이/에스 Pd-l1 및 cd137에 결합하는 결합제 및 그의 용도
WO2019036855A1 (en) 2017-08-21 2019-02-28 Adagene Inc. Anti-cd137 molecules and use thereof
US12202911B2 (en) * 2017-10-10 2025-01-21 Numab Therapeutics AG Multispecific antibody comprising CD137 binding domain and PDL1 binding domain
US11718679B2 (en) 2017-10-31 2023-08-08 Compass Therapeutics Llc CD137 antibodies and PD-1 antagonists and uses thereof
TWI701259B (zh) 2017-11-09 2020-08-11 大陸商上海懷越生物科技有限公司 ４﹘１ｂｂ抗體及其製備方法和應用
EP3713961A2 (en) 2017-11-20 2020-09-30 Compass Therapeutics LLC Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof
WO2019104716A1 (en) * 2017-12-01 2019-06-06 Adagene Inc. Methods for using cd137 ligand as biomarker for treatment with anti-cd137 antibody
WO2019121906A1 (en) 2017-12-19 2019-06-27 F-Star Beta Limited Specific pd-l1 binding sequences inserted in a ch3 domain
WO2019148445A1 (en) 2018-02-02 2019-08-08 Adagene Inc. Precision/context-dependent activatable antibodies, and methods of making and using the same
JP2021514953A (ja) * 2018-02-23 2021-06-17 バイスクルテクス・リミテッド 多量体二環式ペプチドリガンド
MA52075A (fr) 2018-03-23 2021-01-27 Lilly Co Eli Anticorps anti-cd137 pour une combinaison avec des anticorps anti-pd-l1
SG11202009791VA (en) * 2018-04-09 2020-11-27 Origincell Therapeutics Co Ltd Anti-pd-l1 antibody and use thereof
TW202003580A (zh) 2018-05-21 2020-01-16 美商坎伯斯治療有限責任公司 用於增強nk細胞對標靶細胞之殺死之組合物及方法
EA202190138A1 (ru) * 2018-06-29 2021-05-27 ЭЛЕКТОР ЭлЭлСи Анти-sirp-бета1 антитела и способы их использования
GB201811415D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-Mesothelin Anti bodies
GB201811450D0 (en) 2018-07-12 2018-08-29 F Star Delta Ltd Mesothelin and CD137 binding molecules
AU2019301204B2 (en) 2018-07-12 2025-10-23 Invox Pharma Limited Antibody molecules that bind PD-L1 and CD137
MX2021000399A (es) 2018-07-12 2021-05-27 F Star Therapeutics Ltd Moleculas de anticuerpo que se unen a cd137 y ox40.
GB201811403D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Antibody molecules
GB201811404D0 (en) * 2018-07-12 2018-08-29 F Star Beta Ltd Anti-CD137 Antibodies
GB201811410D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd OX40 Binding molecules
GB201811408D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd CD137 Binding Molecules
JP7090204B2 (ja) * 2018-07-19 2022-06-23 イーライ リリー アンド カンパニー 免疫チェックポイントを標的とする二重特異性抗体
CN112739339B (zh) 2018-07-23 2024-12-27 海德堡医药研究有限责任公司 抗cd137抗体药物缀合物(adc)在同种异体细胞疗法中的用途
TW202035451A (zh) 2018-07-24 2020-10-01 美商英伊布里克斯公司 含有受限cd3結合域及受體結合區之多重特異性多肽構築體及其使用方法
EP3850012A4 (en) 2018-09-12 2022-06-15 Eucure (Beijing) Biopharma Co., Ltd ANTI-TNFRSF9 ANTIBODIES AND THEIR USES
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
EP3864049A1 (en) 2018-10-11 2021-08-18 Inhibrx, Inc. Pd-1 single domain antibodies and therapeutic compositions thereof
CA3115089A1 (en) 2018-10-11 2020-04-16 Inhibrx, Inc. Dll3 single domain antibodies and therapeutic compositions thereof
MY206649A (en) * 2018-11-30 2024-12-30 I Mab Biopharma Us Ltd Anti-pd-l1/anti-4-1bb bispecific antibodies and uses thereof
WO2020142624A1 (en) * 2019-01-02 2020-07-09 Qlsf Biotherapeutics Inc. Cd137 agonist antibodies and uses thereof
JP7695698B2 (ja) * 2019-01-14 2025-06-19 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 細胞内部移行をモジュレートするための組成物および方法
SG11202109163YA (en) * 2019-02-26 2021-09-29 Sorrento Therapeutics Inc Antigen binding proteins that bind bcma
AU2020263959A1 (en) 2019-04-24 2021-11-25 Heidelberg Pharma Research Gmbh Amatoxin antibody-drug conjugates and uses thereof
WO2020247290A1 (en) * 2019-06-04 2020-12-10 Academia Sinica Ligands targed to epidermal growth factor receptors and compositions for use in treating tumors
AU2020308463A1 (en) * 2019-06-26 2022-02-17 Ap Biosciences, Inc. Antibodies for T-cell activation
EP4041772A4 (en) * 2019-10-11 2024-04-24 Nanjing Leads Biolabs Co., Ltd. 4-1BB-BINDING ANTIBODIES AND USES THEREOF
US20230068663A1 (en) * 2020-02-05 2023-03-02 The Board Of Regents Of The University Of Texas System Novel lilrb2 antibodies and uses thereof
CN115605228A (zh) * 2020-04-17 2023-01-13 苏州丁孚靶点生物技术有限公司（Cn） 一种特异性结合cd137的制剂及其用途
CA3180665A1 (en) 2020-05-19 2021-11-25 Boehringer Ingelheim International Gmbh Binding molecules for the treatment of cancer
CN113842456B (zh) * 2020-06-28 2022-07-26 上海齐鲁制药研究中心有限公司 一种抗人4-1bb的单克隆抗体制剂及其用途
CN116194124A (zh) * 2020-07-31 2023-05-30 中外制药株式会社 包含表达嵌合受体的细胞的药物组合物
CN116199778B (zh) * 2021-12-01 2025-06-03 上海君实生物医药科技股份有限公司 抗4-1bb抗体及其用途
CN115975032B (zh) * 2022-12-19 2024-06-07 华润生物医药有限公司 一种cldn18.2抗体及其应用
WO2025049858A1 (en) * 2023-09-01 2025-03-06 Amgen Inc. Molecules for treatment of cancer
WO2025189194A1 (en) * 2024-03-08 2025-09-12 Dana-Farber Cancer Institute, Inc. Antibodies against vegf and methods of use thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY27087A1 (es) * 2001-01-05 2002-06-20 Pfizer Anticuerpos contra el receptor del factor de crecimiento similar a insulina
DE60232895D1 (de) 2001-10-09 2009-08-20 Mayo Foundation Verwendung von agonistischen 4-1bb antikörpern zur erhöhung der immunantwort
US20030223989A1 (en) * 2002-04-18 2003-12-04 Pluenneke John D. CD137 agonists to treat patients with IgE-mediated conditions
US7288638B2 (en) * 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
WO2006088447A1 (en) * 2005-02-15 2006-08-24 Gtc Biotherapeutics, Inc. An anti-cd137 antibody as an agent in the treatement of cancer and glycosylation variants thereof
SG10201912092VA (en) 2010-09-09 2020-02-27 Pfizer 4-1bb binding molecules
RU2620071C2 (ru) * 2010-11-17 2017-05-22 Чугаи Сеияку Кабушики Каиша Мультиспецифическая связывающая антиген молекула, которая обладает альтернативной функцией к функции фактора свертывания крови viii
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
AU2016219772A1 (en) 2015-02-22 2017-09-21 Sorrento Therapeutics, Inc. Antibody therapeutics that bind CD137
JP2018510151A (ja) * 2015-03-06 2018-04-12 ソレント・セラピューティクス・インコーポレイテッド Ｔｉｍ３に結合する抗体医薬
TW202035451A (zh) * 2018-07-24 2020-10-01 美商英伊布里克斯公司 含有受限cd3結合域及受體結合區之多重特異性多肽構築體及其使用方法
EP3864049A1 (en) * 2018-10-11 2021-08-18 Inhibrx, Inc. Pd-1 single domain antibodies and therapeutic compositions thereof

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018133139A1 (zh) 2017-01-21 2018-07-26 宁波知明生物科技有限公司 芍药苷-6'-o-苯磺酸酯在治疗干燥综合征的应用
US11459394B2 (en) 2017-02-24 2022-10-04 Macrogenics, Inc. Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereof
TWI788327B (zh) * 2017-02-24 2023-01-01 美商宏觀基因股份有限公司 能夠結合cd137和腫瘤抗原的雙特異性結合分子及其用途
US11942149B2 (en) 2017-02-24 2024-03-26 Macrogenics, Inc. Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereof
TWI842672B (zh) * 2017-04-13 2024-05-21 美商艾吉納斯公司 抗ｃｄ１３７抗體及其使用方法

Also Published As

Publication number Publication date
EP3258959A4 (en) 2018-10-17
WO2016134358A1 (en) 2016-08-25
CN107921104A (zh) 2018-04-17
KR20180016972A (ko) 2018-02-20
US10259881B2 (en) 2019-04-16
IL254088A0 (en) 2017-10-31
US11180568B2 (en) 2021-11-23
US10233251B2 (en) 2019-03-19
US20160244528A1 (en) 2016-08-25
EP3258959A1 (en) 2017-12-27
JP2018508509A (ja) 2018-03-29
AR105313A1 (es) 2017-09-27
US20220025064A1 (en) 2022-01-27
AU2016219772A1 (en) 2017-09-21
CA2977257A1 (en) 2016-08-25
US20170226215A1 (en) 2017-08-10
US20190161554A1 (en) 2019-05-30
MX2017010793A (es) 2018-07-06

Similar Documents

Publication Publication Date Title
US11180568B2 (en) Antibody therapeutics that bind CD137
JP7137646B2 (ja) Ｃｄ４７に結合する抗体医薬
US11999792B2 (en) Antibody therapeutics that bind CD38
US10927171B2 (en) Antibody therapeutics that bind TIM3
CN108271359B (zh) 结合ctla4的抗体治疗剂
HK1253584B (zh) 与cd38结合的抗体治疗剂